Table 2.
Preoperative disease status and treatment.
| Variables | N or Median | % or IQR |
|---|---|---|
| Interval from the diagnosis to operation, months | 10.9 | 8.5–18.2 |
| Interval from the initiation of TKI immediately before surgery to the actual operation, months | 9.8 | 7.8–12.9 |
| TKI before surgery | ||
| Gefitinib | 15 | 34.1% |
| Afatinib | 4 | 9.1% |
| Erlotinib | 1 | 2.3% |
| Osimertinib | 12 | 27.3% |
| - First-line | 6 | 13.6% |
| - Later-line based on the acquired T790M mutation | 6 | 13.6% |
| Alectinib | 7 | 15.9% |
| - First-line | 5 | 11.4% |
| - Later-line | 2 | 4.5% |
| Crizotinib | 4 | 9.1% |
| Lorlatinib | 1 | 2.3% |
| Best response to TKI immediately before surgery | ||
| Partial response | 41 | 93.2% |
| Stable disease | 3 | 6.8% |
| Preoperative local control for metastatic site | 21 | 47.7% |
| Surgery | 4 | 9.1% |
| - Brain | 3 | 6.8% |
| - Lymph node | 1 | 2.3% |
| Radiation therapy | 15 | 34.1% |
| - Brain | 8 | 18.2% |
| - Bone | 5 | 11.4% |
| - Brain and bone | 2 | 4.5% |
| Surgery with radiation therapy | 2 | 4.5% |
| - Brain | 2 | 4.5% |
| Preoperative number of distant metastases | ||
| 0 | 22 | 50.0% |
| 1–2 | 9 | 20.5% |
| 3–5 | 6 | 13.6% |
| >5 | 7 | 15.9% |
| Preoperative primary lesion status | ||
| Partial response | 6 | 13.6% |
| Stable disease | 30 | 68.2% |
| Progressive disease | 8 | 18.2% |
| Preoperative metastatic lesion status | ||
| Radiologic “No-evidence-of-disease” status | 19 | 43.2% |
| Partial response | 2 | 4.5% |
| Stable disease | 21 | 47.7% |
| Progressive disease | 2 | 4.5% |
| Intent of surgery | ||
| Residual lesions | 34 | 77.3% |
| Progressive lesions | 10 | 22.7% |